

Press Release

2022-11-21



Genetic Analysis AS announces the outcome of the warrant exercise

Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS's ("GA" or the "Company") warrants of series TO 1, issued in connection with the Company's IPO of units in September/October 2021, ended. No warrants of series TO 1 have been exercised. The reason for this is deemed to be that the subscription price for the exercise of warrants of series TO 1 has exceeded the current share price during the entire exercise period.

During the period November 2 until November 16, 2022, holders of warrants of series TO 1 were, for each warrant, entitled to subscribe for one (1) new share in GA, at a subscription price set to NOK 9.30 per share. No warrants have been exercised, and therefore, the share capital and the number of shares in the Company remain unchanged.

For more information about warrants of series TO 1, please contact:

Eilert Aamodt, CFO

E-mail: ea@genetic-analysis.com

Website: www.genetic-analysis.com

For more information about GA, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

This is a translation of the Swedish original. If there is any inconsistency between the English and Swedish versions, the Swedish version shall prevail.

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information, visit Genetic Analysis' webpage: www.genetic-analysis.com